Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccination response in immunocompromised hematology patients
NL-OMON24355Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Mar 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam UMC. Primary endpoint: Protection category at 28 days after standard vaccination. Started Mar 2021; status: active, not recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON24355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24355.